Amoxicillin

Generic Name: Amoxicillin

Brand Names: Amoxil, Augmentin, Clavulin, Moxatag, Omeclamox, Prevpac, Talicia, Voquezna 14 Day Dualpak 20;500, Voquezna 14 Day Triplepak 20;500;500

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₉N_₃O_₅S

CAS Number: 26787-78-0

Unique Ingredient Identifier: 9EM05410Q9

Background: Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972. Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin.

Amoxicillin was granted FDA approval on 18 January 1974.

Indication: Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections. Amoxicillin is given with omeprazole in the treatment of Helicobacter pylori (H. pylori) infection.

Amoxicillin is used in combination with vonoprazan and clarithromycin as co-packaged triple therapy or in combination with vonoprazan as co-packaged dual therapy to treat H. pylori infection in adults.

Associated Conditions: Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Bacterial Infections, Community Acquired Pneumonia (CAP), Duodenal ulcer caused by helicobacter pylori, Genitourinary tract infection, Helicobacter Pylori Infection, Lower Respiratory Tract Infection (LRTI), Peptic Ulcer With H. Pylori Infection, Sinusitis, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Acute, uncomplicated Gonorrhea, Ear, nose, and throat infections

Clinical Trials

Safety and Efficacy of Triple and Quadruple Regimens as First Line Therapy for Management of Helicobacter Pylori Infection in Egyptians

Phase 4

Completed

Conditions: H.Pylori Infection

Interventions: Drug: Clarithromycin 500Mg Tab
Drug: Omeprazole 20 MG Oral Tablet
Drug: Amoxicillin 500Mg Tab

First Posted Date: 2024-03-18

Last Posted Date: 2024-03-18

Lead Sponsor: Helwan University

Target Recruit Count: 60

Registration Number: NCT06315478

Locations: 🇪🇬
Badr hospital, Cairo, Egypt

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

Phase 3

Recruiting

Conditions: Penicillin Allergy

Interventions: Drug: Amoxicillin 62.5mg
Drug: Amoxicillin 250 MG
Drug: Placebo
Drug: Amoxicillin 187.5mg

First Posted Date: 2024-03-12

Last Posted Date: 2025-05-01

Lead Sponsor: James Tarbox, MD

Target Recruit Count: 380

Registration Number: NCT06303128

Locations: 🇺🇸
Texas Tech University Health Sciences Center, Lubbock, Texas, United States

Effect of Gut Microbiota After High-dose Dual Therapy Combined With Probiotics for Helicobacter Pylori Eradication

Not Applicable

Completed

Conditions: Metabolic Disturbance
Gut Microbiota
Helicobacter Pylori Eradication

Interventions: Drug: Vonoprazan
Drug: Amoxicillin
Drug: Bacillus subtilis enteric-coated capsules

First Posted Date: 2024-03-05

Last Posted Date: 2025-05-13

Lead Sponsor: Zhongshan Hospital (Xiamen), Fudan University

Target Recruit Count: 72

Registration Number: NCT06292546

Locations: 🇨🇳
Zhongshan Hospital (Xiamen), Fudan University, Xiamen, Fujian, China

Stopping Pneumonia Antibiotherapy Regimen Early

Phase 4

Not yet recruiting

Conditions: Community-acquired Pneumonia
Child, Only

First Posted Date: 2024-03-04

Last Posted Date: 2024-05-20

Lead Sponsor: University Hospital, Montpellier

Target Recruit Count: 1100

Registration Number: NCT06291012

Locations: 🇫🇷
CHU de Montpellier, Montpellier, France

Autoflor -Lyophilized Capsulated Autological FMT to Restore Gut Microbiome After Treatment With Antibiotics

Not Applicable

Not yet recruiting

Conditions: Microbial Colonization
Antibiotic Side Effect

Interventions: Other: FMT
Other: Placebo
Drug: Amox Clav

First Posted Date: 2024-02-09

Last Posted Date: 2024-02-14

Lead Sponsor: Otto Helve

Target Recruit Count: 40

Registration Number: NCT06250413

Locations: 🇫🇮
Helsinki University Hospital, Helsinki, Uusimaa, Finland

Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward

Phase 3

Recruiting

Conditions: Community-acquired Pneumonia

Interventions: Drug: Amoxicillin/clavulanate
Drug: Amoxicillin

First Posted Date: 2024-01-29

Last Posted Date: 2024-10-30

Lead Sponsor: Nantes University Hospital

Target Recruit Count: 326

Registration Number: NCT06229288

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
Chu Angers, Angers, France
🇫🇷
CHU Avicenne AP-HP, Bobigny, France

and more 9 locations

Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection

Conditions: Helicobacter Pylori Infection

Interventions: Drug: Bismuth Subcitrate
Drug: Esomeprazole
Drug: Metronidazole
Drug: Amoxicillin
Drug: Clarithromycin
Drug: Levofloxacin

First Posted Date: 2024-01-22

Last Posted Date: 2024-02-09

Lead Sponsor: National Institute of Public Health, Slovenia

Target Recruit Count: 2000

Registration Number: NCT06216639

Locations: 🇸🇮
Community Healthcare Center dr. Adolf Drolc Maribor (HCM), Maribor, Slovenia

Tailored Vs. Empirical Helicobacter Pylori Infection Treatment

Phase 4

Not yet recruiting

Conditions: Helicobacter Pylori Infection

Interventions: Diagnostic Test: Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test
Drug: Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®)
Drug: PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days
Drug: PPI, amoxicillin 1g and levofloxacin 250 mg, twice daily, for 10 days
Drug: Bismuth quadruple therapy (Pylera®) for 10 days